FDA set to evaluate use of ‘ecstasy’ for treating PTSD

Midomafetamine (MDMA)-assisted therapy may soon be approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-traumatic stress disorder (PTSD). The agency is set to deliberate on its recommendation June 4, bringing in a panel of outside experts to weigh in. 

The application was submitted by Lykos Therapeutics, which is seeking the ability to investigate MDMA-assisted therapies and develop new drugs. MDMA currently has a Schedule 1 classification with the Drug Enforcement Administration (DEA), which designates a substance the agency believes to have no medicinal value. 

However, Lykos contends MDA—more commonly known as “ecstasy”—could be a powerful treatment tool, and it backs its claim with two late-stage studies. The company earned a New Drug Application approval from the FDA in February to study MDA in combination with psychotherapy and other psychiatric interventions. 

"This will be the first MDMA-assisted therapy and psychedelic-assisted therapy to be reviewed by the Psychopharmacologic Drugs Advisory Committee, a significant milestone in the field of psychedelic medicine, resulting from decades of clinical research and advocacy," Amy Emerson, CEO of Lykos Therapeutics said in a statement. "We look forward to the opportunity to discuss the comprehensive data package of investigational MDMA and how, if approved, it may be used as a prescription treatment in combination with psychological intervention in adults with PTSD."

The June 4 meeting will mark the first time in 25 years the FDA has examined a new potential treatment for PTSD. To date, no psychedelic-based therapy has been approved in the U.S.

Chad Van Alstin Health Imaging Health Exec

Chad is an award-winning writer and editor with over 15 years of experience working in media. He has a decade-long professional background in healthcare, working as a writer and in public relations.

Around the web

Compensation for heart specialists continues to climb. What does this say about cardiology as a whole? Could private equity's rising influence bring about change? We spoke to MedAxiom CEO Jerry Blackwell, MD, MBA, a veteran cardiologist himself, to learn more.

The American College of Cardiology has shared its perspective on new CMS payment policies, highlighting revenue concerns while providing key details for cardiologists and other cardiology professionals. 

As debate simmers over how best to regulate AI, experts continue to offer guidance on where to start, how to proceed and what to emphasize. A new resource models its recommendations on what its authors call the “SETO Loop.”